Skip to main content
TipRanks
Go Ultimate75% OFF

Xeris Pharmaceuticals (0A8E) AI Stock Analysis

0 Followers
GB:0A8E

Xeris Pharmaceuticals

(LSE:0A8E)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Accelerating Revenue GrowthStrong product demand is translating into substantial revenue growth, while the raised 2026 outlook indicates management sees momentum continuing beyond a single quarter. This scale can support greater commercial investment and improve operating leverage as the portfolio expands.
Negative Factors
Elevated Balance Sheet LeverageHigh leverage remains a material constraint even as equity has improved from prior negative levels. Debt substantially exceeds the equity base, which can limit financial flexibility, increase sensitivity to any slowdown in growth, and restrict the resources available for sustained investment.

Xeris Pharmaceuticals (0A8E) vs. iShares MSCI United Kingdom ETF (EWC)

-25%0%25%50%75%100%125%150%GB:0A8E+142.36%EWC+17.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.07B
Dividend Yield
―
Average Volume (3M)
4,491
Price to Earnings (P/E)
-416.1
Beta (1Y)
0.96
Revenue Growth
38.37%
EPS Growth
63.43%
Country
UK
Employees
435
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Xeris Pharmaceuticals Business Overview & Revenue Model

Company Description

Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfo...

Xeris Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:57.22%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentPositive

The call was strongly positive, with record third-quarter revenue, substantial Recorlev growth, improving Gvoke prescription demand, continued KEVEYIS growth, higher Adjusted EBITDA and net income, strengthened intellectual property, and raised 2026 and 2030 revenue outlooks. The primary negative items were Gvoke net revenue being reduced by a $4 million one-time Medicaid gross-to-net adjustment, ongoing prior authorization requirements for Recorlev, and higher commercial and operating expenses.

Positive Updates

Record Third-Quarter Revenue and Raised 2026 Guidance
Total third-quarter revenue was $107.2 million, up 44% year-over-year and 16% sequentially. Net product revenue was $106.3 million, up 43% or $32.2 million year-over-year. Based on the strong performance, Xeris raised full-year 2026 total revenue guidance to $395 million-$405 million, representing approximately 37% growth at the midpoint.

Negative Updates

Gvoke Net Revenue Declined Year-Over-Year
Gvoke generated $21.7 million of net revenue in the third quarter, compared with $25.2 million in the third quarter of 2025. Prescription demand grew 5% year-over-year, but revenue was offset by a $4 million one-time gross-to-net adjustment in the Medicaid channel.

Company Guidance

For full-year 2026, Xeris raised total revenue guidance to $395 million-$405 million, representing approximately 37% growth at the midpoint; gross margin guidance remains unchanged, with continued improvement versus prior year expected, R&D expenses are expected to increase approximately $15 million compared to 2025 versus the prior expectation of a $25 million increase, and SG&A is expected to increase approximately $60 million compared to 2025 versus the prior expectation of $50 million. Adjusted EBITDA grew from $34 million-$65 million through the first three quarters, and continued Adjusted EBITDA growth is expected through the remainder of the year. Beyond 2026, Xeris expects more than $1 billion in total revenue in 2030 versus its previous outlook of $750 million, sees Recorlev on a path to $1 billion in annual net revenue three to four years sooner than previously projected, and expects to initiate the XP-8121 Cornerstone phase III study by year-end, with top-line data expected in late 2028 and potential approval and launch in 2030; XP-8121 has peak sales potential of $1 billion-$3 billion.

Xeris Pharmaceuticals Risk Analysis

Xeris Pharmaceuticals disclosed 83 risk factors in its most recent earnings report. Xeris Pharmaceuticals reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Xeris Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A8E against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
ADMAADMA82Outperform$3.02B17.0742.56%―6.26%-10.51%
HRMYHRMY77Outperform$1.94B10.6318.55%―19.79%-4.89%
MNKDMNKD55Neutral$1.31B-17.13139.41%―31.74%-344.30%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
BCRXBCRX49Neutral$1.93B-5.5294.36%―60.30%-3028.57%
PHVSPHVS41Neutral$2.27B-10.54-67.76%――2.74%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%GB:0A8EBCRXMNKDADMAHRMYPHVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A8E and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A8EXeris Pharmaceuticals16.739.67137.07%
BCRXBioCryst Pharmaceuticals7.500.578.23%
MNKDMannKind Corporation4.07-0.93-18.60%
ADMAADMA Biologics Inc13.63-2.32-14.55%
HRMYHarmony Biosciences Holdings, Inc.33.01-0.30-0.90%
PHVSPharvaris N.V.32.287.7431.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.